Median Technologies Raises €50 Million in Capital Increase

On June 3, 2026, Median Technologies announced a successful €50 million capital increase. Institutional and retail investors oversubscribed the €40 million global offering multiple times, indicating strong market interest. An additional €10 million was raised through the Reserved Offering to key investors.

The proceeds will fund the deployment of eyonis® LCS, an AI-based cancer diagnostic tool, in the U.S. and Europe, and advance its clinical capabilities. Following this transaction, Median expects its cash runway to last until the first half of 2028, potentially extending to mid-2029 with warrant exercises from 2025.

The new shares, priced at €5.00 and representing 31% of existing share capital, will be traded on Euronext Growth Paris. The capital increase also diversifies Median’s shareholder base, including significant participation from Lion Point Capital and others.